Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in men today. Although virusbased gene therapy is a promising strategy to combat advanced prostate cancer, its current effectiveness is limited partially due to inefficient cellular transduction in vivo. To overcome this obstacle, conditional oncolytic viruses (such as conditional replication adenovirus (CRAD)) are developed to speci�cally target prostate without (or with minimal) systemic toxicity due to viral selfreplication. In this study, we have analy�ed and compared three prostate-speci�c promoters (PSA, probasin, and MMTV LTR) for their speci�city and activity both in vitro and in vivo. Both mice model with xenogra prostate tumor model and canine model were used. e best PSP was selected to construct a prostate-speci�c oncolytic adenovirus (CRAD) by controlling the adenoviral E1 region. e efficacy and speci�city of CRAD on prostate cancer cells were examined in cell culture and animal models.
Introduction
Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer deaths in American men today with an estimated 241,740 new cases of prostate cancer and 28,170 deaths estimated in year 2012 [1] . Although virus-based gene therapy is a promising strategy to combat advanced prostate cancer, its current effectiveness is limited partially due to inefficient cellular transduction by therapeutic viral vectors in vivo. To overcome this obstacle, conditional oncolytic viruses (such as conditional replication adenovirus (CRAD)) are developed to speci�cally target prostate without (or with minimal) systemic toxicity due to viral "oncolytic" self-replication.
e adenovirus early region 1 (E1) gene, which comprises E1a and E1b, encodes the viral early proteins that are necessary for adenoviral replication and the consequent oncolysis of permissive host cells. E1-deleted (including E1a-deleted) adenoviruses are replication defective and are commonly used as viral vectors to carry therapeutic genes for gene therapy. Replication-competent viruses, also known as oncolytic viruses, replicate within transduced cells and force these cells into a lytic cycle. Released virus is then able to infect neighboring cells until all susceptible cells are eliminated. eoretically, a large tumor burden could be effectively eradicated using a small dose of an oncolytic virus. erefore, strategies to use conditional oncolytic virus, or the so-called attenuated replication-competent viruses, to speci�cally target prostate tissue have been developed [2] [3] [4] . e idea behind this study is to place the Ad5 E1 region in cis complementation (i.e., use E1 as a transgene) back into an E1-deleted, replication-defective adenovirus under the control of a prostate-speci�c promoter (PSP). us, E1 protein expression will be con�ned strictly to the prostate tissues and render this a conditional oncolytic virus (CRAD) within the prostate.
A number of PSPs have been de�ned over the years that include, but not limited to, promoters of prostate-speci�c antigen (PSA), probasin (PB), mouse mammary tumor virus (MMTV LTR), prostate-speci�c membrane antigen (PSMA), human glandular kallikrein 2 (hK2), and prostatic steroidbinding protein C3. Among them, we have extensively studied three of them: PSA, PB, and MMTV promoters. PSA is a protease that is, for all practical purposes, exclusively expressed in prostate [5] . PSA is overproduced by prostate cancer and elevated serum PSA level correlates with the volume of prostate cancer burden [5] [6] [7] . Circulating PSApositive cells are also strongly associated with metastatic prostate cancer [8] . By using an expression vector, a 680 bp PSA promoter isolated from a prostate cancer patient demonstrated the prostate-speci�c expression of the reporter gene [9] . e PSA promoter has an androgen response element (ARE) and its activation requires both the androgen receptor (AR) and its ligand, androgen, to be present. PB, a rat prostate protein, is also expressed selectively in prostate [10] . e rat PB gene promoter (454 bp) contains ARE [11] and directs a hormonal and developmental regulated expression, of a heterologous gene, speci�cally to the prostate in transgenic mice [12] . Transgenic mice bearing PB promoter fused to simian virus 40 large tumor antigen gene all consistently develop prostate adenocarcinoma [13] . Similarly, the MMTV LTR has speci�city for both breast and prostate tissues as determined by studies in both cultured cells and transgenic mice [14] [15] [16] . Retroviruses carrying MMTV LTR-antisense c-myc effectively inhibit the growth of prostate cancer DU145 cells in vivo [17] . MMTV LTR-TGF transgenic mice have transgene expression and biological changes that are exclusive to the breast in female mice [18, 19] and prostate in male mice [20] . e 1.1 kb MMTV LTR appears to have higher prostate-speci�c expression of transgene than that of fulllength MMTV LTR in transgenic mice [5] .
In this study, a systemic comparison of three PSPs (a −650/+30 bp PSA, a −426/+28 bp PB, and a Cla I truncated 1.1 kb MMTV LTR) activity and speci�city in the canine and mouse models followed by a PSP-driven E1-mediated oncolytic approach on prostate cancer has been conducted. We compared PSA, PB, and MMTV LTR for their promoter activity and tissue speci�city side by side in canine and mouse models, as well as in both prostate and nonprostate cells in vitro and in vivo. e best PSP among the three, the PSA promoter, was selected to drive Ad5 E1 region to generate a prostate-speci�c CRAD, AdPSAE1. e e�cacy and speci�city of AdPSAE1 as a potential therapeutic vector for prostate cancer gene therapy were analyzed.
Materials and Methods

2.�. Construction of Adenoviruses Containin� Prostate-S�eci�c
Promoter (PSP) Fused to lacZ. PB/SV40t is an expression vector containing a 454 bp 5 ′ upstream region of PB gene [12] . To make AdPBlacZ, a 3.2 kb lacZ ( -galactosidase) gene containing a nuclear localization signal at the 5 ′ upstream was released from plasmid pPD1.27 (a derivative of pPD16.43 [21] ) by Hind III and Dra I and ligated to PB/SV40t which had been cut by EcoR V, so that lacZ was placed downstream of the 456 bp PB promoter. e resultant plasmid was cut by Pst I and Apa I to release a PB-lacZ-polyA cassette. Aer polishing the ends, the cassette was ligated to an E1a-deleted adenoviral shuttle vector (Genetic erapy Inc., Gaithersburg, MD, USA), whose endogenous RSV promoter had been removed, to generate the resultant recombinant adenoviral shuttle vector pPBlacZ.
A 680 bp 5 ′ upstream region (−650/+30) of PSA gene and a Cla I-truncated 1.1 kb MMTV LTR were used as PSA promoter and MMTV promoter. Adenoviral shuttle vectors pMMTVlacZ and pPSAlacZ were generated by replacing PB promoter in pPBlacZ with MMTV LTR and PSA promoter, respectively. Brie�y, pPBlacZ was cut by Sal I and Xba I� the released lacZ shuttle vector backbone was ligated to a 1.1 kb MMTV promoter which was derived from pMAMneo (Stratagene, Lo Jolla, CA, USA) by cut with Cla I and Nhe I. e resultant recombinant adenoviral shuttle vector was pMMTVlacZ. A 650 bp PSA PCR product was formed by PCR using plasmid containing 5 ′ upstream sequence of PSA gene as template and two primers which were speci�c to the PSA 5 ′ upstream region and also introduced two restriction sites, Sal I and Xba I, one at the end of each primer, respectively. e 650 bp fragment of PSA promoter was puri�ed and cut with Sal I and Xba 1, then ligated to pPBlacZ whose PB promoter was removed by Sal I and Xba I. e resultant recombinant shuttle vector was pPSAlacZ. All the structures of recombinant adenoviral shuttle vectors were con�rmed by DNA sequencing.
Recombinant adenovirus AdPBlacZ, AdMMTVlacZ, and AdPSAlacZ were generated via in vivo recombination in 293 cells by the cotransfection of pJM17, an adenoviral genome plasmid, with the corresponding shuttle vectors pPBlacZ, pMMTVlacZ, and pPSAlacZ, respectively. e individual adenoviral plaques were screened by direct plaque-screening method as described previously [22] . By the similar way, AdRSVlacZ, in which lacZ gene was under the control of a constitutive Rous Sarcoma virus (RSV) promoter, was generated [23] . e schematic diagrams of these four adenoviral vectors were illustrated in Figure 1 . Single viral clones were propagated in 293 cells and puri�ed by BD Adeno-X Virus Puri�cation Kits (BD Biosciences, Palo Alto, CA, USA). e viral titers were determined by plaque assays in 293 cells [24] .
Delivery of Adenoviral Vectors to the Prostate of the Canine
Model. Using a canine model, each of the adenoviral vectors of AdRSVlacZ, AdPBlacZ, AdPSAlacZ, and AdMMTVlacZ (4.8 × 10
9 pfu each to one dog) was diluted in 1 mL of 0.9 M saline and delivered to one anesthetized dog (average age of one and half years old and average weight of 22 kg) by intraprostatic injection. Brie�y, laparotomy was performed and 0.25 mL viral solution was directly injected into each quadrant of the prostate (4 × 0.25 mL = 1 mL total). At 72 hr, the dogs were sacri�ced and various organs (prostate, liver, lung, spleen, bladder, brain, heart, kidney, external and internal iliac arteries, gonads, and vas deferens) were obtained at necropsy. e animal protocol was approved by the institutional IACUC. was isolated using RNeasy Total RNA Kit (Qiagen) from organs and tissues according to the Manufacturer's protocol. Aer the treatment of total RNA with RNase-free DNase I (Gibco BRL), reverse-transcriptase reaction was carried out using Superscript II RT (Gibco BRL) according to the Manufacturer's protocol. An aliquot of the RT mixture was subsequently used for the PCR reaction. e primers were speci�c to E. coli lacZ gene and resulted in a 1036 bp PCR ampli�cation fragment [26] . Primer 1 was 5
-Galactosidase ( -Gal
′ -GCCGACCGCACGCCGCATCCAGC-3 ′ and Primer 2 was 5 ′ -CGCCGCGCCACTGGTGTGGGCC-3 ′ . PCR was performed in 50 mL total volume containing 5 to 10 L above RT mixture, in a �nal concentration of 4 mM MgCl 2 , 50 mM KCl, 0.2 mM each of dNTPs, 20 mM Tris-HCl (pH 8.4), 2 mM each of the primers, and 2.5 units of Taq DNA polymerase (Gibco BRL). e reaction was carried out at 94 ∘ C for 4 min, then for 30 cycles at 94 ∘ C for 1 min, 60 ∘ C for 2 min, and 72 ∘ C for 2 min, followed by 72 ∘ C for 10 min.
Southern
Blot. e standard Southern blot transfer of PCR or RT-PCR cDNA products from agarose gel to Nylon membrane (Hybond-N + Amersham Life Science, Buckinghamshire, UK) was performed as previously described [6] . e 860 bp and 1036 bp PCR products (see above) from positive control plasmids were puri�ed and used 4 BioMed Research International as the probe for PCR and RT-PCR Southern, respectively. e probe was labeled by a-32 P-dCTP using random primer method (Prime-It II Kit, Stratagene, La Jolla, CA, USA). e membrane was hybridized with the probe in Rapid-hyb buffer (Amersham Life Science) according to the Manufacturer's protocol. e membrane was exposed to a Kodak X-ray �lm between two intensifying screens at −80 ∘ C for autoradiography. Rat gliosarcoma 9L cells were grown in D-MEM medium with 10% FBS. All cells were grown in medium containing 100 units/mL penicillin, 100 ug/mL streptomycin at 37 ∘ C in a 5% CO 2 atmosphere. 1 × 10 10 pfu prostate-speci�c Ad-lacZ were injected directly onto tumor site. e mice were euthanatized in 3 days and the tumors and other organs were harvested and sections were prepared. e animal protocol was approved by the institutional IACUC.
Cell
Adenoviral Transduction In Vivo on Xenogra Tumors.
X-Gal Staining of Xenogra Tumors Transduced by lacZ Adenoviruses.
Tumors samples were �xed in 4% paraformaldehyde for 30 min, then in 30% sucrose in PBS at 4 ∘ C until the samples sank to the bottom of the vial. e samples were then snap-frozen in liquid nitrogen in O.C.T. medium (Tissue-Tek/Sakura, Torrance, CA, USA) and processed to cryosections by a Cryostat. e cryosections were �xed in formalin for 30 sec then processed for X-gal staining as a measure of lacZ expression as described in [27] . For tumor whole-mount staining, tumors were �xed in 4% paraformaldehyde for 30 min, washed with PBS three times, and incubated overnight at 37 ∘ C in 1 mg/mL X-gal, 10 mM potassium ferricyanide, 10 mM potassium ferrocyanide, 0.01% sodium deoxycholate, 0.02% NP40, and 2 mM MgCl 2 in PBS. e stained tumors were then post-�xed for 24 hr in 2.5% glutaraldehyde, 1% formaldehyde, and 0.1 M sodium deoxycholate (pH 7.0) in PBS.
Analysis of Potential Oncolytic Effects of AdPSAE1 on Various Cell Lines. Cells (5 × 10
4 per well) were plated in six-well plates; the next day the cells were either untreated or transduced with AdPSAlacZ or AdPSAE1 at the multiplicity of infection (moi) of 1. In brief, adenoviral infection of the cell lines was carried out by the addition of the viral solutions to cell monolayers and incubation at 37 ∘ C for 3 h with brief agitation every 15 min during the �rst 90 min incubation. Aer 3 h exposure to virus, the viral solution was deleted and a fresh medium was added to the cells. Aer 6 days of transduction, the medium was removed and the plates were washed twice with PBS. e wells were then completely covered with 2 mL of 1% crystal violet (Sigma, St. Louis, MO, USA) and the plate was allowed to sit 5 min with gentle rocking. Aer washing with water, the plate was allowed to dry at room temperature overnight before it was photographed. Tumor volume was measured every 3 days until the animals were sacri�ced. All of the animals were sacri�ced at day 35 aer viral injection, when mice showed distress or had tumor burdens >15% of their total body weight.
In Vitro Growth Inhibition
Results
�.1. Study of PSP Activity and S�eci�city in Canine Model.
To compare the speci�city and activity of three different PSP (PSA, PB, and MMTV LTR promoters), we constructed replication-defective adenoviruses containing lacZ reporter gene under the control of PSA, PB, and MMTV promoters, respectively (Figure 1 ). In addition, we also constructed lacZ virus (AdRSVlacZ) under the control of the nonspeci�c, constitutively active RSV promoter for comparison.
First, the activity and expression of reporter gene lacZ driven by these PSP were compared in vivo using a canine model by direct intraprostatic injection of these Ad-lacZ vectors. At 72-hour postinjection, various other organs including the prostate were harvested. To determine whether adenovirus dissemination occurred following intraprostatic injection, DNA was extracted from various canine tissues and was subjected to PCR Southern blot analysis for adenoviral sequences by using PCR primers �anked an 860 bp sequence of adenoviral genome [23] . We found that all adenoviral vector-injected prostates had an intense 860 bp signal band on agarose gel (not shown), con�rming that the majority of adenoviral transduction occurred in the prostate. Interestingly, adenoviral sequences were found in tissues other than the prostate, suggesting that there was adenoviral dissemination following intraprostatic injection. For example, control viral vector AdRSVlacZ disseminated to the vas deferens (perhaps as a result of re�ux from the ejaculatory ducts of the injected prostate) and external iliac artery. AdPSAlacZ and AdMMTVlacZ were also detected in vas deferens as well as in bladder tissues. Intraprostatic injection of AdPBlacZ resulted in adenoviral vector dissemination to the bladder, heart, and liver ( Figure 2) . Nevertheless, the majority of adenoviral vector DNA was found in the prostate following the intraprostatic viral injection. Adenovirus may disseminate to other organs and tissues, primarily bladder and vas deferens. e presence of adenoviral DNA in heart, blood vessels, and liver tissues may be explained by the fact that these organs overall receive a higher percentage of cardiac output (blood �ow) than other organs.
Next, in order to determine the speci�city of the PSP, we examined whether transgene lacZ was expressed in tissues containing adenoviral DNA. Total RNA was extracted from various canine tissues and subjected to RT-PCR analysis. e primers used for RT-PCR were speci�c for E. coli lacZ and �anked a 1036 bp internal sequence of the lacZ gene. Southern hybridization of RT-PCR gel (Figure 3) showed that a 1036 bp band was present in prostates following intraprostatic adenoviral injection. e control viral vector AdRSVlacZ had lacZ mRNA expression in all tissues where adenoviral vectors had disseminated (compare Figures 3(a)  and 2(a) ). is was expected as RSV has nonspeci�c promoter activity. In contrast, AdPSAlacZ and AdMMTVlacZ had no expression of lacZ in vas deferens and bladder (compare Figures 3(b) , 2(b), 3(c), and 2(c)). Similarly, AdPBlacZ lacked detectable lacZ mRNA transcripts in bladder, heart, and liver (compare Figures 3(d) and 2(d) ). Taken together, the results of Figures 2 and 3 con�rmed that although prostate-speci�c adenoviral vectors do disseminate following intraprostatic injection, the adenoviral lacZ transgene was expressed only in the prostate. Interestingly, some organs such as liver, lung, spleen, bladder, and kidney, which had no detectable adenoviral DNA sequences by PCR Southern, had lacZ mRNA expression by RT-PCR Southern hybridization, implying that RT-PCR of lacZ transgene may be more sensitive than PCR of adenoviral sequences (compare Figures 3(a) and 2(a) ). e integrity and equality of the RNA samples from various canine tissues was con�rmed by RT-PCR of the housekeeping gene -actin from the same cDNA pools used for RT-PCR of lacZ (not shown).
Study of PSP Activity in Canine Prostates and Xenogra
Tumors in Mice. e activity of these three PSPs was compared in the canine prostates aer corresponding Ad-lacZ intraprostatic injection. PSA and PB promoters showed better PSP activity than MMTV LTR in vivo: protein extracts isolated from canine prostates were used for the colorimetric -galactosidase assay to measure the lacZ enzymatic activity. Among the three PSP-driven Ad-lacZ, AdPSAlacZ had the highest activity (2.86 -gal units/per mg protein), compared to AdPBlacZ (2.29 -gal units/per mg protein) and AdMMTVlacZ (1.86 -gal units/per mg protein) ( Figure  4) . �owever, the activity of the PSP is signi�cantly lower than that of the constitutively active RSV promoter. As demonstrated by the whole-mount X-gal staining of the xenogra prostate tumors that grew in mice and were intratumoral injected with various Ad-lacZ viruses (Figure 5 )). is indicates that PSP had one log less promoter activity in vivo compared to that of constitutively active promoter such as RSV.
PSA��riven E� E��ression E�ectively and S�eci�cally
Inhibits Prostate Cancer Cell Growth In Vitro. As the 620 bp PSA promoter demonstrates the best promoter activity (and equal or better speci�city) among the three PSP we analyzed (Figures 3 and 4) , we have generated a prostate-speci�c, conditional oncolytic adenovirus, AdPSAE1 (Figure 6 ), by replacing the lacZ transgene of AdPSAlacZ ( Figure 1) ; the resultant AdPSAE1 is exactly the same genome structure as AdPSAE1 except that the E1 gene has replaced lacZ gene, so that the PSA-E1 expression cassette replaces the native wild-type E1 region in Ad5 genome ( Figure 6 ). As E1 is required and sufficient for adenovirus self-replication and consequent oncolysis in the host cells, accordingly, this strategy allows the expression of E1 protein under the control of a prostate speci�c promoter (PSA, as previously demonstrated by AdPSAlacZ in regulating lacZ expression shown above), enabling the adenovirus to replicate and enter the oncolytic cycle only in prostate cells. e antiprostate tumor efficacy and speci�city of AdPSAE1 were examined in vitro and in vivo in both prostate and nonprostate cancer models.
e potential oncolytic cell-killing effects of AdPSAE1 were analyzed in various cancer cells. e human prostate cancer lines PPC-1 and LNCaP and nonprostate cancer cell lines RT4 (human bladder cancer), MCF-7 (human breast cancer), and 9L (human glioma) were infected with AdPSAE1 or control virus AdPSAlacZ at moi of 1. Viable cells were stained with crystal violet 6 days aer infection and were compared to untreated control cells ( Figure 6 ). As dead cells typically detach, crystal violet stains only those viable cells that remain attached to the culture dish. As shown in Figures 6(a) and 6(b), AdPSAE1 (right well) almost completely wiped out all PPC-1 and LNCaP cells, whereas AdPSAlacZ (middle well) had no cell-killing effects as compared to the untreated control (le well), respectively. On the other hand, AdPSAE1 had no cell-killing effects on RT4 (Figure 6(c) F 2: Adenoviral DNA sequence PCR Southern hybridization. DNA extracted from prostates and various organs at necropsy were sub�ected to PCR using primers speci�c to Ad� genome. e expected PCR product of adenoviral sequences was a �6� bp band (shown by arrows). e PCR gel was transferred to a Nylon membrane by the Southern blot and the blot was hybridized with labeled probe which was the puri�ed �6� bp PCR product from control adenoviral plasmid. Shown are the PCR Southern blots of dogs in�ected intraprostatically by AdRSVlacZ (a), AdPSAlacZ (b), AdMMTVlacZ (c), and AdPBlacZ (d).
( Figure 6 virus AdPSAlacZ at moi of 1 in vitro, and the cell numbers were monitored. As shown in Figure 7 , signi�cant growth inhibition was observed starting at day 4 aer AdPSAE1 infection, with complete growth inhibition at day 6 for both prostate cancer cell lines PPC-1 and LNCaP. AdPSAlacZ transduction did not cause signi�cant growth inhibition in either of these cell lines (Figures 7(a) and 7(b) ). On day 6 aer in vitro viral transduction at moi of 1, AdPSAE1 transduction signi�cantly reduced the numbers of PPC-1 and LNCaP cells to 81.6% and 96.9% of untreated control values, whereas the control virus AdPSAlacZ transduction resulted in minor and insigni�cant growth inhibition (Figures 7(a) and 7(b) ). In contrast, AdPSAE1 had no signi�cant cell-killing or growth inhibition effects towards the nonprostate cancer cells RT4, MCF-7, and 9L when compared to the untreated control and control virus AdPSAlacZ transduced groups (Figure 7(c) ). ese results suggest that, in vitro, AdPSAE1 effectively leads to prostate-speci�c oncolytic killing. To ensure that selective viral replication accounted for the cell killing in AdPSAE1 transduced cells, RT-PCR was performed using primers speci�c to Ad� E1a gene and followed by Southern blot hybridization [23] to examine the E1a mRNA expression in AdPSAE1-transduced cells. We found that only LNCaP and PPC-1 cells had positive E1a RT-PCR product whereas RT4, MCF-7, and 9L cells did not (not shown), indicating that E1a was selectively expressed in prostate cancer cells. We also performed RCA (replicationcomplement adenovirus) assay by sequential infection of target cells (prostate and nonprostate cells) with AdPSAE1 
�.�. ��e�i�� ���ression o� Transgene �riven �� the P�A Promoter in the Xenogra Prostate Tumors in Animal Model.
To demonstrate PSA-driven expression speci�cally in the prostate in the mouse model, we examine the speci�city of prostate-speci�c promoters xenogra tumors from both prostate origin and nonprostate cancer cells were established in nude mice. A dose of 1 × 10 10 pfu AdPSAlacZ was injected into subcutaneous xenogra tumors derived from human prostate cancer PPC-1 cells or human bladder cancer RT4 cells. As a positive control, AdRSVlacZ [23] , an adenovirus containing the lacZ gene under the control of a constitutively active RSV promoter, was injected into xenogra tumors at a dose of 5 × 10 9 pfu. LacZ expression was determined through X-gal staining of the cryosections of the tumors 72 h following viral injection. Untransduced control PPC-1 (Figure 8(a) ) and RT4 (Figure 8(b) ) tumors did not express detectable endogenous lacZ. AdPSAlacZ transduced PPC-1 tumors contained X-gal positive (blue stained) cells ( Figure  8(c) ), whereas AdPSAlacZ transduced RT4 tumors did not (Figure 8(d) ). In contrast, both PPC-1 (Figure 8 When tumors developed to about 200 mm 3 , a single dose of AdPSAE1 was injected directly into the tumor in both cancer cell models. As shown in Figure 9 (a) for the PPC-1 tumor model, both untreated tumors and tumors treated with control virus AdPSAlacZ grew rapidly and at a similar rate. In contrast, the AdPSAE1-treated group showed an effective suppression of this rapid growth. By day 35 aer viral injection, the group treated with AdPSAE1 had a remarkable 61.8% reduction of tumor size as compared to the untreated group (Figure 9(a) ). On the other hand, the same single dose of AdPSAE1 injected into the RT4 xenogra tumors failed to result in signi�cant growth inhibition, as compared to the untreated RT4 tumor group (Figure 9(b) ). e Western of tumor extracts con�rmed that only PPC-1 tumors treated with AdPSAE1 showed detectable E1 protein expression (not shown). ese results suggest that AdPSAE1 is able to speci�cally inhibit prostate tumor growth in vivo.
Discussion
To prevent unintended cytotoxic gene expression in nontargeted tissues during gene therapy (particularly when a suicide gene or oncolytic gene such as E1 is the expressed gene), tissue and�or cell-type speci�c promoters are required in order to tightly control the transgene expression. While it is ideal to have a cancer cell speci�c promoter to target diseased cells and spare the normal cells in the same organs, in the case when such a promoter is not available and the organ is not vital (as in the case of prostate cancer therapy), an organ�tissue-speci�c promoter would work as well. In this study, three PSPs were compared and the best one (PSA promoter) was used to control E1-mediated oncolytic therapy for prostate cancer.
Most current gene therapy clinical trials are using viral vectors that are self-replication defective. ese replication de�cient viruses were designed for the safety reason in order to prevent viral oncolysis and replication in the host. ese safe gene-transfer vehicles represent the early-stage gene therapy viral vectors which deliver therapeutic transgenes without exposing host cells to the danger of viral lytic cycle. However, the low transduction rate of viral vectors in vivo con�nes therapeutic transgene expression to only those cells along the injected needle track due to the viral inability to pass the transgene to neighboring cells. Consequently, the effectiveness of a therapeutic viral vector is directly correlated to its transduction efficiency. Although the bystander effect of certain therapeutic transgenes in the suicide gene therapy strategy for cancer helps to increase some therapeutic index, its effect is limited. Tumor cells cannot be 100% transduced with a single treatment. Untransduced tumor cells survive, divide, and eventually offset the therapeutic effects posed by the initial viral transduction. erefore, repeated viral injections aimed at infecting those tumor cells not infected in the �rst round of viral transduction and those newly divided tumor daughter cells are required to achieve a successful gene therapy. However, due to the strong host immunogenic responses caused by adenoviral vectors, the second and subsequent rounds of adenoviral administration possess signi�cantly reduced therapeutic effects in vivo [28, 29] . To overcome this obstacle, approaches that employ conditional oncolytic viruses, also called attenuated replicationcompetent viruses (such as CRAD), have been proposed for cancer gene therapy. e principle of conditional oncolytic viruses is that those viruses are engineered such that they can speci�cally target a desired cell type, or they are several orders of magnitude more susceptible to cause oncolytic cell lysis in the desired target cells than in the nontargeted cells. Our study showed that a 680 bp (−650/+30) PSA promoter is sufficient enough to drive a prostate-speci�c transgene expression in both canine prostates and xenogra tumors in mice. is PSA promoter-driven E1 expression led to a complete killing on prostate cancer cells in vitro and a signi�cant inhibition of prostate tumor growth in mice with no toxic effects on nonprostate cells or tumors.
In the study, we observed that the activity of PSA promoter, while maintaining its faithful tissue-speci�c expression, is noticeably weaker (by at least 10-fold) compared to the constitutive active RSV promoter (compare Figure 5 (a) with 5(c) and Figure 8 (c) with 8(e), resp.). is implies that, as a tradeoff for the tissue speci�city, the expression of a therapeutic transgene driven by the PSA promoter will be much lower than that of a constitutively active promoter. Still, this may not present a major issue in our case because we are using an oncolytic strategy in which the therapeutic transgene, itself, is the Ad5 E1 gene. e relatively low degree of PSP activity may suffice, bring E1 expression to a level that causes oncolysis. eoretically, only low levels of E1 expression are required to initiate and maintain the continuing viral oncolytic cycle to eradicate all prostate cells inside a tumor. In this study, we have demonstrated that at moi of 1, AdPSAE1 was able to completely eradicate all cancerous prostate cells in vitro (Figures 6 and 7) . Similarly, in our in vivo study, at viral doses (i.e., intratumoral injection of 5 × 10 6 pfu AdPSAE1 per tumor of 200 mm 3 size, Figure 9 ) much lower than that of the typical E1-deleted adenoviral vectors we have routinely used (i.e., intratumoral injection of 5 × 10 9 pfu E1-deleted adenovirus containing a therapeutic gene per tumor of 100 mm 3 size, [30, 31] ), AdPSAE1 exhibited an equivalent inhibition ability for xenogra prostate tumor growth as those by E1-deleted adenovirus at a much higher dose. However, we were still unable to completely eradicate tumors using AdPSAE1 treatment in vivo (Figure 9(a) ). is may be partially due to the insufficient production of the E1 protein in vivo by the relatively weak prostate-speci�c promoter.
e idea of using conditional oncolytic viruses for cancer therapy (virotherapy) is a very promising strategy that may make a large advance toward the optimal goal-complete eradication of primary tumor cells and the targeting of tumor metastases. While there are still a number of hurdles to overcome, one apparent emphasis for this oncolytic approach includes tissue/cell-type speci�c targeting in order to ensure safety; the other is targeting metastatic prostate cancer cells by systemic administration. A study to evaluate the biodistribution and toxicity of a replication-competent adenovirus following intraprostatic injection demonstrated that although the virus persisted in the urogenital tract and liver, most of the toxicity was minimal and self-limiting. Most importantly, there was no germ-line transmission of viral genes [32] . One way to control viral spread is to incorporate a prodrug enzyme gene in the CRAD, so the prodrug can be used as desired to suppress viral replication effectively. An example of that approach is the designing of a replicationcompetent, E1b-attenuated adenovirus containing CD/HSV-TK fusion gene; not only the suicide gene system allows for the utilization of double-suicide gene therapy, but also it provides a means to eliminate the virus and controls viral spread whenever needed [33] . Moreover, to target metastatic and circulating prostate cancer cells by systemic administration, tissue-speci�c promoters (such as PSP) can be combined to modi�ed viral vectors with tropism to cancer cells to have a dual regulation control at the tissue-speci�c level (transcriptional targeting) and cell type-speci�c level (transductional targeting) [34, 35] .
In addition to tissue-speci�c-promoter-(such as PSPs) driven oncolytic approach, tumor-speci�c promoters including survivin, carcinoembryonic antigen (CEA), and telomerase have also been used in regulated E1A expression in oncolytic adenoviral approach. Survivin overexpresses in several human tumors including gliomas [36] and prostate cancer [37] ; thus surviving promoter is a good candidate for tumor-speci�c regulated E1a expression in gliomas [38, 39] and both PSA-producing and -nonproducing prostate cancers. Likewise, a CEA promoter-driven E1a replicationcompetent adenovirus, OV798, preferentially replicates in and kills CEA-producing colorectal cancer cells, but its replication is attenuated by 1000-fold in the CEA-negative cell lines [40] . e telomerase (hTR and hTERT) promoters are active in most cancer cells but not in normal cells, thus making the telomerase promoter-controlled E1a replicationcompetent adenovirus an attractive approach for tumorspeci�c oncolytic targeting [41] . Studies using telomerasespeci�c oncolytic viruses demonstrated their effective antitumor abilities both in vitro and in vivo [42] [43] [44] [45] . In addition, the promoter of the CREBBP/EP300 inhibitory protein 1 (CRI1), a gene speci�cally expressed in malignant pleural mesothelioma, was used to drive E1a-mediated virotherapy that speci�cally kills malignant mesothelioma cells but not normal cells [46] . Other tumor-speci�c promoters used to drive E1-mediated virotherapy against various cancers include mucin-1 promoter [47] , osteocalcin promoter [48] , AFP promoter [49] , midkine promoter [50] , and COX-2 promoter [51, 52] .
e ongoing efforts for a better understanding of the oncolytic cycle of viral biology and a continued development of cancer-speci�c conditional replication-competent viruses have brought hope closer to generating the ideal oncolytic virus for prostate cancer gene therapy. With signi�cant improvement in viral transductional targeting and transcriptional regulation, we expect that oncolytic virus-based gene therapy will become a potential and effective means for prostate cancer treatment in the near future.
